Teva Takes Another Step Into Biosimilars Market


Published On: May 26th, 2010

The company is currently enrolling 60 patients in Germany and Hungary for a trial comparing its biosimilar drug, TL011, with Rituxan, approved to treat rheumatoid arthritis and two kinds of cancer.

View post: 
Teva Takes Another Step Into Biosimilars Market



Loading...


Comments are closed.